Filters
Documents
Showing 25 of 714 items meeting your criteria.
| Type | Category | Supplier | ||
|---|---|---|---|---|
 | Viral applications: Enhancing AAV transduction | |||
Documents | Transduction | Oz Biosciences | ||
 | In Vitro Transfection, In Vivo Gene Delivery.
Primary Neurons and Neural Cells
Microglial Cells
Brain: In vivo Nucleic Acid Delivery | |||
Documents | Neuroscience | Oz Biosciences | ||
 | INTEGRATED MRNA SERVICE FROM GENE SYNTHESIS TO IVT MRNA PRODUCTION | |||
Documents | Service | Oz Biosciences | ||
 | Magnetic Nanoparticle Technology - Virus Capture, Concentration & Conservation | |||
Documents | Transduction | Oz Biosciences | ||
 | Enhancing lentiviral transduction | |||
Documents | Transduction | Oz Biosciences | ||
 | RESEARCH GRADE ADJUVANTS FOR PROTEIN BASED VACCINES AND mRNA/DNA VACCINES | |||
Documents | Vaccine Adjuvants | Oz Biosciences | ||
 | Lentiviral production | |||
Documents | Transfection | Oz Biosciences | ||
 | THE MOST PROMISING NON-VIRAL DRUG DELIVERY NANOSYSTEMS | |||
Documents | Nanoparticles | Oz Biosciences | ||
 | Adult Stem Cells - Embryonic Stem Cells, Induced Pluripotent Stem Cells (iPS) | |||
Documents | Stem Cells | Oz Biosciences | ||
 | High Throughput Screening
In vivo Transfection
3D Transfection | |||
Documents | Transfection | Oz Biosciences | ||
 | Large-Scale Protein Production | |||
Documents | Transfection | Oz Biosciences | ||
 | Magnetic-Assisted Transfection
Enhance Transfection Efficiency
Gene Expression - Gene Silencing, CRISPR/Cas9 Genome Editing, In vivo & Ex vivo Transfection | |||
Documents | Transfection | Oz Biosciences | ||
 | Neuroscience Applications:
Hippocampal, Cortical, Motor Neurons, Dopaminergic, Glioblastoma, Neuroblastoma, DRG, Neural Stem cells, Oligodendrocytes...
Successfully transfected | |||
Documents | Transfection | Oz Biosciences | ||
 | Vaccine, Gene Reporter, Genome Editing & Gene Replacement mRNAs | |||
Documents | RNA | Oz Biosciences | ||
 | HIGH-QUALITY VIRAL ENHANCER | |||
Documents | Transduction | Oz Biosciences | ||
 | Protein Quantification Assays
Enzyme Detection - Reporter Gene Assays
Viability / Apoptosis / Stress Assays | |||
Documents | Cell Based Assays | Oz Biosciences | ||
 | Abnova provides a range of Tumour-Associated Antigens of CAR T Cell Therapy. | |||
Documents | Cancer | Abnova Corporation | ||
 | Abnova provides a range of antibodies for research into TNF-TRAF Signalling. | |||
Documents | Immunology | Abnova Corporation | ||
 | Abnova provides a range of reagents for research into the role of Tumour Necrosis Factor in Amyotrophic Lateral Sclerosis. | |||
Documents | Neuroscience | Abnova Corporation | ||
 | T-cell-dependent antibody response (TDAR) to an antigen is a gold standard in vivo assessment of immunotoxicity at the preclinical stage of drug discovery. Abnova offers a wide variety of ELISA kits for biomarkers used in TDAR assays. | |||
Documents | ELISA | Abnova Corporation | ||
 | Approximately there are 10% of patients with NSCLC in the US and 35% in Asia harboring EGFR mutations. EGFR mutations occur within exons 18–21 encoding a portion of the EGFR kinase domain. These mutations affect the kinase activity of EGFR, leading to downstream pro-survival signaling pathways.
EGFR mutations confer sensitivity of EGFR TKI and as well as are involved in mechanisms of acquired resistance to EGFR TKI therapy. Resistance can occur through secondary resistance mutations (such as T790M) occurring in the ATP-binding domain. | |||
Documents | Cancer | Abnova Corporation | ||
 | Also known as NS7; B-raf; BRAF1; RAFB1; B-RAF1, is a member of the RAF family of serine/threonine protein kinases activating the MAP kinase/ERK-signaling pathway and normally involved in regulating cell differentiation, proliferation, growth, and apoptosis. BRAF V600E mutation drives tumor growth by hyperactivating the extracellular signal regulated kinase (ERK) signaling pathway in the absence of any extracellular stimuli. | |||
Documents | Cancer | Abnova Corporation | ||
 | Exhausted T cells have been identified to accumulate in tumour microenvironment (TME) and fail to eliminate cancer cells. The exhaustion is characterised by the expression of multiple inhibitory molecules, including PD-1 and CTLA4. PD-1/PD-L1 signaling antagonises TCR signaling and induces the transcription of exhaustion-related genes. Both PD-1/PD-L1 and CTLA4 signaling inhibit the pathways that promote cell cycle arrest in T cells. The inhibition of PI3K/Akt/mTOR pathway mediated by PD-1/PD-L1 or CTLA4 also leads to decreases in glycolysis and amino acid metabolism and suppresses mitochondrial biogenesis. These exhaustion-related changes result in dysfunctional T cells, which are obstacles to effective tumour immunotherapy. | |||
Documents | Cancer | Abnova Corporation | ||
 | Neutralising antibodies are able to block the interaction between viruses and host cells, which can potentially stop the infection. Abnova has developed a group of SARS-CoV-2 S monoclonal antibodies, which are neutralising mouse monoclonal antibodies targeting recombinant SARS-CoV-2 spike protein. | |||
Documents | COVID-19 | Abnova Corporation | ||
 | Abnova provides a range of antibodies specific for renal cell carcinomas. | |||
Documents | Cancer | Abnova Corporation | ||